Publication

Liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12-and 18-month survival rates from the phase 3 NAPOLI 3 trial

O'Reilly, E. M.
; 
Melisi, D.
; 
Macarulla, T.
; 
Roberto, A.
; 
Cid, P.
; 
Chandana, S. R.
; 
De La Fouchardiere, C.
; 
Dean, A. P.
; 
Kiss, I.
; 
Lee, W. J.
... show 10 more
Citations
Altmetric:
Abstract
Authors
O'Reilly, E. M.
Melisi, D.
Macarulla, T.
Roberto, A.
Cid, P.
Chandana, S. R.
De La Fouchardiere, C.
Dean, A. P.
Kiss, I.
Lee, W. J.
Goetze, T. O.
Van Cutsem, E.
Paulson, S.
Bekaii-Saab, T. S.
Pant, S.
Hubner, Richard A
Xiao, Z. M.
Chen, H. Y.
Benzaghou, F.
Wainberg, Z. A.
Affiliation
Memorial Sloan Kettering Cancer Center, New York, NY
Description
Date
2023
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
O'Reilly EM, Melisi D, Macarulla T, Roberto A, Cid P, Chandana SR, et al. Liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12-and 18-month survival rates from the phase 3 NAPOLI 3 trial. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772000831.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626639
Embedded videos